The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. [electronic resource]
Producer: 20201124Description: 192-204 p. digitalISSN:- 1876-4479
- Aged
- Antibodies, Monoclonal, Humanized -- adverse effects
- Colitis, Ulcerative -- drug therapy
- Crohn Disease -- drug therapy
- Digestive System Diseases -- chemically induced
- Female
- Gastrointestinal Agents -- adverse effects
- Gastrointestinal Diseases -- chemically induced
- Humans
- Infusions, Intravenous -- adverse effects
- Lupus Erythematosus, Systemic -- chemically induced
- Male
- Neoplasms -- chemically induced
- Product Surveillance, Postmarketing
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.